Skip to content

Revvity

NYSE: RVTY · USD

Revvity revenue72

Quarterly and annual revenue from company filings.

Business drivers

Business lines and operating measures.

Life Sciences Solutions revenue

Reported quarterly Life Sciences Solutions revenue. Quarterly figures · USD

Life Sciences Solutions revenue. Reported quarterly Life Sciences Solutions revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jul 5, 2026From Apr 6, 2026301,028,000Filed Aug 11, 2026
Apr 5, 2026From Dec 29, 2025299,996,000Filed May 12, 2026
Jun 29, 2025From Mar 31, 2025298,052,000Filed Aug 11, 2026
Mar 30, 2025From Dec 30, 2024286,453,000Filed May 12, 2026

Software revenue

Reported quarterly Software revenue. Quarterly figures · USD

Software revenue. Reported quarterly Software revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jul 5, 2026From Apr 6, 202657,671,000Filed Aug 11, 2026
Apr 5, 2026From Dec 29, 202561,849,000Filed May 12, 2026
Jun 29, 2025From Mar 31, 202567,846,000Filed Aug 11, 2026
Mar 30, 2025From Dec 30, 202453,942,000Filed May 12, 2026

Immunodiagnostics revenue

Reported quarterly Immunodiagnostics revenue. Quarterly figures · USD

Immunodiagnostics revenue. Reported quarterly Immunodiagnostics revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jul 5, 2026From Apr 6, 2026214,758,000Filed Aug 11, 2026
Apr 5, 2026From Dec 29, 2025201,831,000Filed May 12, 2026
Jun 29, 2025From Mar 31, 2025218,818,000Filed Aug 11, 2026
Mar 30, 2025From Dec 30, 2024197,562,000Filed May 12, 2026

Reproductive Health revenue

Reported quarterly Reproductive Health revenue. Quarterly figures · USD

Reproductive Health revenue. Reported quarterly Reproductive Health revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jul 5, 2026From Apr 6, 2026156,231,000Filed Aug 11, 2026
Apr 5, 2026From Dec 29, 2025147,442,000Filed May 12, 2026
Jun 29, 2025From Mar 31, 2025135,568,000Filed Aug 11, 2026
Mar 30, 2025From Dec 30, 2024126,805,000Filed May 12, 2026

Independent series; they may overlap and do not form an additive breakdown.

  • The supplied quarterly histories are not continuous.
  • The proposals measure business-line revenue rather than operating volumes.

Products & projects

Vanadis® NIPT

◦The Vanadis® NIPT offering, a non-PCR non-sequencing fully automated cfDNA technology for use in any laboratory for screening common trisomies in the pregnant population.

Filed · source for Vanadis® NIPT

Revenue history

USD millions · Fiscal periods
Jul 4, 2010 through Jul 5, 2026

Quarterly data

Revvity quarterly financial data in USD millions. FY denotes the company's fiscal year. YTD covers reported quarters only.
Fiscal quarterEndedTotal revenueUSD millions
FY 2026 Q2Jul 5, 2026729.688, +2.6% versus FY 2026 Q1
FY 2026 Q1Apr 5, 2026711.118, −7.9% versus FY 2025 Q4
FY 2025 Q4Dec 28, 2025772.056, +10.5% versus FY 2025 Q3
FY 2025 Q3Sep 28, 2025698.949, −3.0% versus FY 2025 Q2
FY 2025 Q2Jun 29, 2025720.284, +8.4% versus FY 2025 Q1
FY 2025 Q1Mar 30, 2025664.762, −8.9% versus FY 2024 Q4
FY 2024 Q4Dec 29, 2024729.372, +6.6% versus FY 2024 Q3
FY 2024 Q3Sep 29, 2024684.049, −1.1% versus FY 2024 Q2
FY 2024 Q2Jun 30, 2024691.685, +6.4% versus FY 2024 Q1
FY 2024 Q1Mar 31, 2024649.92, −6.6% versus FY 2023 Q4
FY 2023 Q4Dec 31, 2023695.901, +3.8% versus FY 2023 Q3
FY 2023 Q3Oct 1, 2023670.739, −5.4% versus FY 2023 Q2
FY 2023 Q2Jul 2, 2023709.066, +5.1% versus FY 2023 Q1
FY 2023 Q1Apr 2, 2023674.865, −9.0% versus FY 2022 Q4
FY 2022 Q4Jan 1, 2023741.214, +4.1% versus FY 2022 Q3
FY 2022 Q3Oct 2, 2022711.803, −42.1% versus FY 2022 Q2
FY 2022 Q2Jul 3, 20221,229.569, −2.4% versus FY 2022 Q1
FY 2022 Q1Apr 3, 20221,259.442, +22.5% versus FY 2021 Q4
FY 2021 Q4Jan 2, 20221,027.91, −11.9% versus FY 2021 Q3
FY 2021 Q3Oct 3, 20211,166.684, −5.0% versus FY 2021 Q2
FY 2021 Q2Jul 4, 20211,228.471, −6.1% versus FY 2021 Q1
FY 2021 Q1Apr 4, 20211,307.689, −3.5% versus FY 2020 Q4
FY 2020 Q4Jan 3, 20211,354.606, +40.5% versus FY 2020 Q3
FY 2020 Q3Oct 4, 2020964.025, +18.8% versus FY 2020 Q2
FY 2020 Q2Jul 5, 2020811.718, +24.4% versus FY 2020 Q1
FY 2020 Q1Apr 5, 2020652.396, −19.0% versus FY 2019 Q4
FY 2019 Q4Dec 29, 2019805.496, +13.9% versus FY 2019 Q3
FY 2019 Q3Sep 29, 2019706.923, −2.2% versus FY 2019 Q2
FY 2019 Q2Jun 30, 2019722.517, +11.4% versus FY 2019 Q1
FY 2019 Q1Mar 31, 2019648.737, −14.2% versus FY 2018 Q4
FY 2018 Q4Dec 30, 2018756.349, +12.2% versus FY 2018 Q3
FY 2018 Q3Sep 30, 2018674.313, −4.1% versus FY 2018 Q2
FY 2018 Q2Jul 1, 2018703.362, +9.2% versus FY 2018 Q1
FY 2018 Q1Apr 1, 2018643.972, +0.4% versus FY 2017 Q4
FY 2017 Q4Dec 31, 2017641.63, +15.8% versus FY 2017 Q3
FY 2017 Q3Oct 1, 2017554.275, +1.3% versus FY 2017 Q2
FY 2017 Q2Jul 2, 2017546.962, +6.4% versus FY 2017 Q1
FY 2017 Q1Apr 2, 2017514.115, −9.3% versus FY 2016 Q4
FY 2016 Q4Jan 1, 2017566.77, +3.4% versus FY 2016 Q3
FY 2016 Q3Oct 2, 2016548.054, −4.3% versus FY 2016 Q2
FY 2016 Q2Jul 3, 2016572.667, +6.3% versus FY 2016 Q1
FY 2016 Q1Apr 3, 2016538.684, −11.4% versus FY 2015 Q4
FY 2015 Q4Jan 3, 2016608.116, +7.9% versus FY 2015 Q3
FY 2015 Q3Oct 4, 2015563.436, −0.1% versus FY 2015 Q2
FY 2015 Q2Jun 28, 2015563.906, +7.0% versus FY 2015 Q1
FY 2015 Q1Mar 29, 2015526.901, −13.4% versus FY 2014 Q4
FY 2014 Q4Dec 28, 2014608.39, +12.2% versus FY 2014 Q3
FY 2014 Q3Sep 28, 2014542.049, −2.5% versus FY 2014 Q2
FY 2014 Q2Jun 29, 2014556.17, +4.6% versus FY 2014 Q1
FY 2014 Q1Mar 30, 2014531.904, −10.3% versus FY 2013 Q4
FY 2013 Q4Dec 29, 2013593.28, +13.2% versus FY 2013 Q3
FY 2013 Q3Sep 29, 2013524.277, −3.5% versus FY 2013 Q2
FY 2013 Q2Jun 30, 2013543.297, +7.5% versus FY 2013 Q1
FY 2013 Q1Mar 31, 2013505.378, −11.8% versus FY 2012 Q4
FY 2012 Q4Dec 30, 2012572.921, +12.4% versus FY 2012 Q3
FY 2012 Q3Sep 30, 2012509.604, −2.3% versus FY 2012 Q2
FY 2012 Q2Jul 1, 2012521.79, +2.1% versus FY 2012 Q1
FY 2012 Q1Apr 1, 2012510.89, −5.4% versus FY 2011 Q4
FY 2011 Q4Jan 1, 2012540.192, +19.1% versus FY 2011 Q3
FY 2011 Q3Oct 2, 2011453.74, −5.4% versus FY 2011 Q2
FY 2011 Q2Jul 3, 2011479.491, +7.1% versus FY 2011 Q1
FY 2011 Q1Apr 3, 2011447.864, −4.7% versus FY 2010 Q4
FY 2010 Q4Jan 2, 2011469.97, +12.1% versus FY 2010 Q3
FY 2010 Q3Oct 3, 2010419.143, −15.8% versus FY 2010 Q2
FY 2010 Q2Jul 4, 2010497.839, Change unavailable versus FY 2010 Q1
Sources and definitions

Figures from official company filings and financial reports, in the reported currency. FY identifies the fiscal year; the end date identifies the calendar period. Last checked Oct 19, 2026.

Annual values come from annual filings. Historical quarters retain their reporting basis; rounding and reclassifications can make their sum differ from the annual figure. YTD sums the available fiscal quarters and compares the same quarters of the previous fiscal year.

Missing values are shown as unavailable. Fourth quarters use reported values where available, otherwise the annual amount less the matching nine-month amount.

Total revenue
Reported consolidated revenue from the issuer filing. Each observation identifies its accounting concept; bank net revenue is net of interest expense when that concept is reported.
Annual and quarterly differences
  • FY 2014 · Total revenue: annual 2,237.219, quarter sum 2,238.513 USD millions.
  • FY 2016 · Total revenue: annual 2,115.517, quarter sum 2,226.175 USD millions.
  • FY 2021 · Total revenue: annual 5,067.169, quarter sum 4,730.754 USD millions.
  • FY 2022 · Total revenue: annual 3,311.822, quarter sum 3,942.028 USD millions.